APO Research
Talk to an analyst

APO RESEARCH · REPORT

Metabotropic Glutamate Receptor 7

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Metabotropic Glutamate Receptor 7 Market Outlook and Growth Opportunities 2026

19 December 2025195 pages

Choose your research edition.

Industry ResearchMetabotropic Glutamate Receptor 7 Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Metabotropic Glutamate Receptor 7 Industry Growth and Trends Forecast to 203272 pages · $3,450 USDMarket StructureGlobal Metabotropic Glutamate Receptor 7 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032176 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Metabotropic Glutamate Receptor 7 Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Metabotropic Glutamate Receptor 7 Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Metabotropic Glutamate Receptor 7 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Metabotropic Glutamate Receptor 7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Metabotropic Glutamate Receptor 7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Metabotropic Glutamate Receptor 7 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Metabotropic Glutamate Receptor 7 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Metabotropic Glutamate Receptor 7 market include Addex Therapeutics Ltd, Aevi Genomic Medicine Inc, Bio-Pharm Solutions Co Ltd and Pragma Therapeutics SAS, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Metabotropic Glutamate Receptor 7 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Metabotropic Glutamate Receptor 7 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Metabotropic Glutamate Receptor 7 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Metabotropic Glutamate Receptor 7 market size, projected growth trends, production technologies, key applications, and end-use industries.

Metabotropic Glutamate Receptor 7 Segment by Company

Addex Therapeutics Ltd

Aevi Genomic Medicine Inc

Bio-Pharm Solutions Co Ltd

Pragma Therapeutics SAS

Metabotropic Glutamate Receptor 7 Segment by Type

PGT-117

JBPOS-0101

ADX-71743

Others

Metabotropic Glutamate Receptor 7 Segment by Application

Infantile Spasm

Generalized Anxiety Disorder

Status Epilepticus

Others

Metabotropic Glutamate Receptor 7 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Metabotropic Glutamate Receptor 7 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Metabotropic Glutamate Receptor 7 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Metabotropic Glutamate Receptor 7 significant trends, drivers, influence factors in global and regions.

6. To analyze Metabotropic Glutamate Receptor 7 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metabotropic Glutamate Receptor 7 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Metabotropic Glutamate Receptor 7 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metabotropic Glutamate Receptor 7.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Metabotropic Glutamate Receptor 7 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Metabotropic Glutamate Receptor 7 industry.

Chapter 3: Detailed analysis of Metabotropic Glutamate Receptor 7 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Metabotropic Glutamate Receptor 7 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Metabotropic Glutamate Receptor 7 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Metabotropic Glutamate Receptor 7 Industry Trends Table 2. Metabotropic Glutamate Receptor 7 Industry Drivers Table 3. Metabotropic Glutamate Receptor 7 Industry Opportunities and Challenges Table 4. Metabotropic Glutamate Receptor 7 Industry Restraints Table 5. Global Metabotropic Glutamate Receptor 7 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Metabotropic Glutamate Receptor 7 Revenue Share by Company (2021-2026) Table 7. Global Metabotropic Glutamate Receptor 7 Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Company (2021-2026) Table 9. Global Metabotropic Glutamate Receptor 7 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Metabotropic Glutamate Receptor 7 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Metabotropic Glutamate Receptor 7 Key Company Manufacturing Base & Headquarters Table 12. Global Metabotropic Glutamate Receptor 7 Company, Product Type & Application Table 13. Global Metabotropic Glutamate Receptor 7 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Metabotropic Glutamate Receptor 7 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of PGT-117 Table 18. Significant Companies of JBPOS-0101 Table 19. Significant Companies of ADX-71743 Table 20. Significant Companies of Others Table 21. Global Metabotropic Glutamate Receptor 7 Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Metabotropic Glutamate Receptor 7 Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Metabotropic Glutamate Receptor 7 Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Type (2021-2026) Table 25. Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Type (2027-2032) Table 26. Global Metabotropic Glutamate Receptor 7 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Metabotropic Glutamate Receptor 7 Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Metabotropic Glutamate Receptor 7 Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Type (2021-2026) Table 30. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Infantile Spasm Table 32. Significant Companies of Generalized Anxiety Disorder Table 33. Significant Companies of Status Epilepticus Table 34. Significant Companies of Others Table 35. Global Metabotropic Glutamate Receptor 7 Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Metabotropic Glutamate Receptor 7 Sales Volume by Application (2021-2026) & (W Units) Table 37. Global Metabotropic Glutamate Receptor 7 Sales Volume by Application (2027-2032) & (W Units) Table 38. Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Application (2021-2026) Table 39. Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Application (2027-2032) Table 40. Global Metabotropic Glutamate Receptor 7 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Metabotropic Glutamate Receptor 7 Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Metabotropic Glutamate Receptor 7 Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Application (2021-2026) Table 44. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Application (2027-2032) Table 45. Global Metabotropic Glutamate Receptor 7 Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Metabotropic Glutamate Receptor 7 Sales by Region (2021-2026) & (W Units) Table 47. Global Metabotropic Glutamate Receptor 7 Sales Market Share by Region (2021-2026) Table 48. Global Metabotropic Glutamate Receptor 7 Sales by Region (2027-2032) & (W Units) Table 49. Global Metabotropic Glutamate Receptor 7 Sales Market Share by Region (2027-2032) Table 50. Global Metabotropic Glutamate Receptor 7 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Metabotropic Glutamate Receptor 7 Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Region (2021-2026) Table 53. Global Metabotropic Glutamate Receptor 7 Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Region (2027-2032) Table 55. Global Metabotropic Glutamate Receptor 7 Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Metabotropic Glutamate Receptor 7 Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Metabotropic Glutamate Receptor 7 Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Global Metabotropic Glutamate Receptor 7 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Metabotropic Glutamate Receptor 7 Sales by Country (2021-2026) & (W Units) Table 60. Global Metabotropic Glutamate Receptor 7 Sales Market Share by Country (2021-2026) Table 61. Global Metabotropic Glutamate Receptor 7 Sales by Country (2027-2032) & (W Units) Table 62. Global Metabotropic Glutamate Receptor 7 Sales Market Share by Country (2027-2032) Table 63. Global Metabotropic Glutamate Receptor 7 Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Metabotropic Glutamate Receptor 7 Sales Value Market Share by Country (2021-2026) Table 65. Global Metabotropic Glutamate Receptor 7 Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Metabotropic Glutamate Receptor 7 Sales Value Market Share by Country (2027-2032) Table 67. Addex Therapeutics Ltd Company Information Table 68. Addex Therapeutics Ltd Business Overview Table 69. Addex Therapeutics Ltd Metabotropic Glutamate Receptor 7 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Addex Therapeutics Ltd Metabotropic Glutamate Receptor 7 Product Portfolio Table 71. Addex Therapeutics Ltd Recent Development Table 72. Aevi Genomic Medicine Inc Company Information Table 73. Aevi Genomic Medicine Inc Business Overview Table 74. Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 7 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 7 Product Portfolio Table 76. Aevi Genomic Medicine Inc Recent Development Table 77. Bio-Pharm Solutions Co Ltd Company Information Table 78. Bio-Pharm Solutions Co Ltd Business Overview Table 79. Bio-Pharm Solutions Co Ltd Metabotropic Glutamate Receptor 7 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Bio-Pharm Solutions Co Ltd Metabotropic Glutamate Receptor 7 Product Portfolio Table 81. Bio-Pharm Solutions Co Ltd Recent Development Table 82. Pragma Therapeutics SAS Company Information Table 83. Pragma Therapeutics SAS Business Overview Table 84. Pragma Therapeutics SAS Metabotropic Glutamate Receptor 7 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Pragma Therapeutics SAS Metabotropic Glutamate Receptor 7 Product Portfolio Table 86. Pragma Therapeutics SAS Recent Development Table 87. Key Raw Materials Table 88. Raw Materials Key Suppliers Table 89. Metabotropic Glutamate Receptor 7 Distributors List Table 90. Metabotropic Glutamate Receptor 7 Customers List Table 91. Research Programs/Design for This Report Table 92. Authors List of This Report Table 93. Secondary Sources Table 94. Primary Sources List of Figures Figure 1. Metabotropic Glutamate Receptor 7 Product Image Figure 2. Global Metabotropic Glutamate Receptor 7 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Metabotropic Glutamate Receptor 7 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Metabotropic Glutamate Receptor 7 Sales (2021-2032) & (W Units) Figure 5. Global Metabotropic Glutamate Receptor 7 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Metabotropic Glutamate Receptor 7 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. PGT-117 Image Figure 10. JBPOS-0101 Image Figure 11. ADX-71743 Image Figure 12. Others Image Figure 13. Global Metabotropic Glutamate Receptor 7 Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Metabotropic Glutamate Receptor 7 Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Type (2021-2032) Figure 16. Global Metabotropic Glutamate Receptor 7 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Metabotropic Glutamate Receptor 7 Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Type (2021-2032) Figure 19. Infantile Spasm Image Figure 20. Generalized Anxiety Disorder Image Figure 21. Status Epilepticus Image Figure 22. Others Image Figure 23. Global Metabotropic Glutamate Receptor 7 Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Metabotropic Glutamate Receptor 7 Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Application (2021-2032) Figure 26. Global Metabotropic Glutamate Receptor 7 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Metabotropic Glutamate Receptor 7 Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Application (2021-2032) Figure 29. Global Metabotropic Glutamate Receptor 7 Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 30. Global Metabotropic Glutamate Receptor 7 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Metabotropic Glutamate Receptor 7 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Metabotropic Glutamate Receptor 7 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Metabotropic Glutamate Receptor 7 Sales Value (2021-2032) & (US$ Million) Figure 34. North America Metabotropic Glutamate Receptor 7 Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Metabotropic Glutamate Receptor 7 Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Metabotropic Glutamate Receptor 7 Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Metabotropic Glutamate Receptor 7 Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Metabotropic Glutamate Receptor 7 Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Metabotropic Glutamate Receptor 7 Sales Value (2021-2032) & (US$ Million) Figure 40. South America Metabotropic Glutamate Receptor 7 Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Metabotropic Glutamate Receptor 7 Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Metabotropic Glutamate Receptor 7 Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Metabotropic Glutamate Receptor 7 Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Metabotropic Glutamate Receptor 7 Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • PGT-117
  • JBPOS-0101
  • ADX-71743
  • Others
Applications
  • Infantile Spasm
  • Generalized Anxiety Disorder
  • Status Epilepticus
  • Others
Companies covered
  • Addex Therapeutics Ltd
  • Aevi Genomic Medicine Inc
  • Bio-Pharm Solutions Co Ltd
  • Pragma Therapeutics SAS

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Metabotropic Glutamate Receptor 7 Sales Value (2021-2032)
  4. 1.2.2 Global Metabotropic Glutamate Receptor 7 Sales Volume (2021-2032)
  5. 1.2.3 Global Metabotropic Glutamate Receptor 7 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Metabotropic Glutamate Receptor 7 Market Dynamics
  1. 2.1 Metabotropic Glutamate Receptor 7 Industry Trends
  2. 2.2 Metabotropic Glutamate Receptor 7 Industry Drivers
  3. 2.3 Metabotropic Glutamate Receptor 7 Industry Opportunities and Challenges
  4. 2.4 Metabotropic Glutamate Receptor 7 Industry Restraints
3 Metabotropic Glutamate Receptor 7 Market by Company
  1. 3.1 Global Metabotropic Glutamate Receptor 7 Company Revenue Ranking in 2025
  2. 3.2 Global Metabotropic Glutamate Receptor 7 Revenue by Company (2021-2026)
  3. 3.3 Global Metabotropic Glutamate Receptor 7 Sales Volume by Company (2021-2026)
  4. 3.4 Global Metabotropic Glutamate Receptor 7 Average Price by Company (2021-2026)
  5. 3.5 Global Metabotropic Glutamate Receptor 7 Company Ranking (2024-2026)
  6. 3.6 Global Metabotropic Glutamate Receptor 7 Company Manufacturing Base and Headquarters
  7. 3.7 Global Metabotropic Glutamate Receptor 7 Company Product Type and Application
  8. 3.8 Global Metabotropic Glutamate Receptor 7 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Metabotropic Glutamate Receptor 7 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Metabotropic Glutamate Receptor 7 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Metabotropic Glutamate Receptor 7 Market by Type
  1. 4.1 Metabotropic Glutamate Receptor 7 Type Introduction
  2. 4.1.1 PGT-117
  3. 4.1.2 JBPOS-0101
  4. 4.1.3 ADX-71743
  5. 4.1.4 Others
  6. 4.2 Global Metabotropic Glutamate Receptor 7 Sales Volume by Type
  7. 4.2.1 Global Metabotropic Glutamate Receptor 7 Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Metabotropic Glutamate Receptor 7 Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Metabotropic Glutamate Receptor 7 Sales Value by Type
  11. 4.3.1 Global Metabotropic Glutamate Receptor 7 Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Metabotropic Glutamate Receptor 7 Sales Value by Type (2021-2032)
  13. 4.3.3 Global Metabotropic Glutamate Receptor 7 Sales Value Share by Type (2021-2032)
5 Metabotropic Glutamate Receptor 7 Market by Application
  1. 5.1 Metabotropic Glutamate Receptor 7 Application Introduction
  2. 5.1.1 Infantile Spasm
  3. 5.1.2 Generalized Anxiety Disorder
  4. 5.1.3 Status Epilepticus
  5. 5.1.4 Others
  6. 5.2 Global Metabotropic Glutamate Receptor 7 Sales Volume by Application
  7. 5.2.1 Global Metabotropic Glutamate Receptor 7 Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Metabotropic Glutamate Receptor 7 Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Metabotropic Glutamate Receptor 7 Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Metabotropic Glutamate Receptor 7 Sales Value by Application
  11. 5.3.1 Global Metabotropic Glutamate Receptor 7 Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Metabotropic Glutamate Receptor 7 Sales Value by Application (2021-2032)
  13. 5.3.3 Global Metabotropic Glutamate Receptor 7 Sales Value Share by Application (2021-2032)
6 Metabotropic Glutamate Receptor 7 Regional Sales and Value Analysis
  1. 6.1 Global Metabotropic Glutamate Receptor 7 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Metabotropic Glutamate Receptor 7 Sales by Region (2021-2032)
  3. 6.2.1 Global Metabotropic Glutamate Receptor 7 Sales by Region: 2021-2026
  4. 6.2.2 Global Metabotropic Glutamate Receptor 7 Sales by Region (2027-2032)
  5. 6.3 Global Metabotropic Glutamate Receptor 7 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Metabotropic Glutamate Receptor 7 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Metabotropic Glutamate Receptor 7 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Metabotropic Glutamate Receptor 7 Sales Value by Region (2027-2032)
  9. 6.5 Global Metabotropic Glutamate Receptor 7 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Metabotropic Glutamate Receptor 7 Sales Value (2021-2032)
  12. 6.6.2 North America Metabotropic Glutamate Receptor 7 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Metabotropic Glutamate Receptor 7 Sales Value (2021-2032)
  15. 6.7.2 Europe Metabotropic Glutamate Receptor 7 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Metabotropic Glutamate Receptor 7 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Metabotropic Glutamate Receptor 7 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Metabotropic Glutamate Receptor 7 Sales Value (2021-2032)
  21. 6.9.2 South America Metabotropic Glutamate Receptor 7 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Metabotropic Glutamate Receptor 7 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Metabotropic Glutamate Receptor 7 Sales Value Share by Country, 2025 VS 2032
7 Metabotropic Glutamate Receptor 7 Country-level Sales and Value Analysis
  1. 7.1 Global Metabotropic Glutamate Receptor 7 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Metabotropic Glutamate Receptor 7 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Metabotropic Glutamate Receptor 7 Sales by Country (2021-2032)
  4. 7.3.1 Global Metabotropic Glutamate Receptor 7 Sales by Country (2021-2026)
  5. 7.3.2 Global Metabotropic Glutamate Receptor 7 Sales by Country (2027-2032)
  6. 7.4 Global Metabotropic Glutamate Receptor 7 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Metabotropic Glutamate Receptor 7 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Metabotropic Glutamate Receptor 7 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Metabotropic Glutamate Receptor 7 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Metabotropic Glutamate Receptor 7 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Metabotropic Glutamate Receptor 7 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Addex Therapeutics Ltd
  2. 8.1.1 Addex Therapeutics Ltd Company Information
  3. 8.1.2 Addex Therapeutics Ltd Business Overview
  4. 8.1.3 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 7 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 7 Product Portfolio
  6. 8.1.5 Addex Therapeutics Ltd Recent Developments
  7. 8.2 Aevi Genomic Medicine Inc
  8. 8.2.1 Aevi Genomic Medicine Inc Company Information
  9. 8.2.2 Aevi Genomic Medicine Inc Business Overview
  10. 8.2.3 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 7 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 7 Product Portfolio
  12. 8.2.5 Aevi Genomic Medicine Inc Recent Developments
  13. 8.3 Bio-Pharm Solutions Co Ltd
  14. 8.3.1 Bio-Pharm Solutions Co Ltd Company Information
  15. 8.3.2 Bio-Pharm Solutions Co Ltd Business Overview
  16. 8.3.3 Bio-Pharm Solutions Co Ltd Metabotropic Glutamate Receptor 7 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Bio-Pharm Solutions Co Ltd Metabotropic Glutamate Receptor 7 Product Portfolio
  18. 8.3.5 Bio-Pharm Solutions Co Ltd Recent Developments
  19. 8.4 Pragma Therapeutics SAS
  20. 8.4.1 Pragma Therapeutics SAS Company Information
  21. 8.4.2 Pragma Therapeutics SAS Business Overview
  22. 8.4.3 Pragma Therapeutics SAS Metabotropic Glutamate Receptor 7 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pragma Therapeutics SAS Metabotropic Glutamate Receptor 7 Product Portfolio
  24. 8.4.5 Pragma Therapeutics SAS Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Metabotropic Glutamate Receptor 7 Value Chain Analysis
  2. 9.1.1 Metabotropic Glutamate Receptor 7 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Metabotropic Glutamate Receptor 7 Sales Mode & Process
  6. 9.2 Metabotropic Glutamate Receptor 7 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Metabotropic Glutamate Receptor 7 Distributors
  9. 9.2.3 Metabotropic Glutamate Receptor 7 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst